Barber et al. just published a fundamentally flawed study on diabetes medicines in JAMA Network Open (JNO). This study wrongly suggests that cost-based pricing accurately values innovative on-patent ...

Case in point: The U.S. Securities and Exchange Commission (SEC) is operated as an independent federal agency, and its annual costs are paid for using transaction-based fees called Section 31 fees.

For firms pursuing outcome-based pricing, this requires a fundamental shift in how they think about their offerings.

The changing landscape of drug pricing policy in the U.S. has implications for the global pace and direction of innovation. Drug policy changes are being influenced by perceptions of the value of ...

Optum Rx has signaled a shift to a cost-based pharmacy reimbursement model that's intended to have pharmacies pay more for brand-name drugs and less for generics. The model will reduce variation in ...